Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study
- Conditions
- Type 1 DiabetesDiabetes, Autoimmune
- Registration Number
- NCT05013346
- Lead Sponsor
- Yaounde Central Hospital
- Brief Summary
Type 1 diabetes has been poorly characterised, with very sparse information available in the literature about the characteristics of the disease in Africa. Atypical young onset diabetes is often reported by clinicians in sub-Saharan Africa, including patients who have the phenotype of type 1 diabetes but do not appear to have an absolute insulin requirement. The onset of type 1 diabetes in many sub-Saharan African populations seem to occur at later ages (20s to 40s) than what is generally seen in Caucasian populations. The investigators seek to characterise young-onset insulin treated diabetes (clinically diagnosed type 1 diabetes) in sub-Saharan Africa;
- Detailed Description
The specific objectives will be to; (1) characterise a population with clinically diagnosed type 1 diabetes and to determine the proportion of islet autoantibody positivity rates and to compare with a similar cohort of patients in the UK, (2) to determine the proportion of participants with retained endogenous insulin secretion (C-peptide \> 600pmol/l) and whether they have evidence of autoimmunity as assessed by islet autoantibody and the type 1 diabetes genetic risk score
Study setting: This study will be a multi-center cross-sectional study of clinically diagnosed type 1 diabetes patients who are currently on insulin treatment who are being followed-up in existing diabetes care centers in 4 sub-Saharan African countries; Cameroon, Uganda, Tanzania and South Africa. Recruitment will take place at regional diabetes care centers which usually serve as the main diabetes treatment hub for many smaller spoke clinics in the sub-region. In Cameroon, the Yaounde Central Hospital and the Bafoussam Regional Hospital will serve as main clinical sites. In Uganda the clinical sites involved are the Mulago National Referral and Teaching Hospital, St. Francis Hospital Nsambya, all in Kampala and the Masaka Regional Referral Hospital. The Muhimbili National Hospital in Dar Es Salaam will serve as the main clinical site in Tanzania. Cameroon, Uganda and Tanzania will carry out primary data collection over the study period while South Africa (University of Witwatersrand Medical School) will provide secondary data consisting of a minimal dataset and relevant collected samples for analysis. All these centers have existing diabetes care clinics with experienced staff who are used to collecting and providing data for research purposes.
Eligibility: All patients with a clinical diagnosis of type 1 diabetes or young-onset insulin treated diabetes, who were diagnosed before the age of 30 years will be eligible to be enrolled into the study. We estimated a minimum total sample size of 500 participants will have a high precision with 95% confidence intervals of 17-25% around a prevalence of 20% for a clinical or biological characteristics (e.g. retained C-peptide or presence of islet auto-antibodies) and 46-54% around a prevalence of 50%.
Sampling method: We will follow a systematic sampling method, enrolling consecutive eligible participants from the different primary collection clinical sites.
Enrollment: All consented patients will be interviewed using a structured pre-tested questionnaire (Data Collection Form) by a trained study staff to collect relevant information; demographic, socioeconomic, lifestyle, family history, history of diabetes and diabetes complications. The questionnaire used in this study is available in English and has been translated into the major local language(s); the appropriate questionnaire is used according to the participant's preference. After the interview, a short clinical examination will be performed to record anthropometric characteristics (weight, height, waist and hip circumferences) and blood pressure.
Using standardized operating procedures (SOPs), saliva, blood and urine samples will be collected from all study participants for biochemical analysis, and biobanking for future studies. Saliva will be used for DNA extraction and for the determination of type 1 genetic risk score (T1D GRS) using a 67 single nucleotide polymorphism score as described by Sharp et al. 2019. Venous whole blood will be used for full blood count and A1c determination. Plasma will be used for random C-peptide determination on the 801 module of the Cobas 8000 analyser and the measuring range will be truncated to \<3pmol/L. Serum creatinine will be measured to assist in the interpretation of the C-peptide result. Islet autoantibodies, GAD, IA2 and ZnT8 will be measured in serum on the RSR Limited ELISA (RSR Limited, Cardiff, U.K.). Dipstick urinalysis will be done, with urinary C-peptide and creatinine measurement for the determination of the urinary C-peptide to creatinine ration (UCPCR). .
Data collected from the different clinical sites using the data collection form will be entered into a centralized data management tool (REDCap). All data will be anonymised before being stored in the data management system.
Ethical consideration: All participants will be required to provide a written informed consent before participating in the study. Refusal to participate will not affect the quality of care of the participants at the clinical sites. The study has received ethical clearance from the National Ethics Committee of Cameroon ( No 2018/12/1252/L/CNERSH/SP), and the Uganda Virus Research Institute (GC/127/19/12/736), Muhimbili National Hospital (MNH/IRB/I/2020/019) and Human Research Ethics Committe, South Africa (M200174).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1200
- Clinical diagnosis of type 1 diabetes at age less than 30 years
- Currently use insulin as a permanent treatment
- Able to consent to study
- Refusal to provide written informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of retained endogenous insulin secretion Baseline Random non-fasting C-peptide level
Islet auto-antibody titre and positivity proportions Baseline GADA, IA-2A, ZnT8A
- Secondary Outcome Measures
Name Time Method Type 1 diabetes genetic risk score Baseline Proportion with T1D GRS \> 50th centile
Trial Locations
- Locations (4)
Uganda Virus Research Institute
🇺🇬Entebbe, Uganda
National Obesity Centre, Yaounde Central Hospital
🇨🇲Yaounde, Centre, Cameroon
Muhimbili National Hospital
🇹🇿Dar Es Salaam, Tanzania
School of Pathology, University of Witwatersrand
🇿🇦Johannesburg, Gauteng, South Africa